Efforts are Underway to Tackle Immunotherapy Resistance in Refractory RCCMarch 14th 2023
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Ipilimumab Yields ‘Limited Effect’ in Refractory Kidney Cancer SubtypeMarch 12th 2023
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
Expert Highlights Armamentarium of Advanced Kidney Cancer TherapiesMarch 11th 2023
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
A Cardiologist’s Approach to Followup For Patients on ADT and Strategies in Multidisciplinary CareMarch 10th 2023
Cardiologist Anees A. Daud, MD, highlights how a cardiologist may followup with patients receiving androgen deprivation therapy and how multidisciplinary care plays a role in this setting.
GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup AnalysisMarch 9th 2023
Shaji Kumar, MD, presents updated data from the GRIFFIN trial investigating combination daratumumab, lenalidomide, bortezomib, and dexamethasone for the treatment of transplant-eligible newly-diagnosed multiple myeloma (NDMM).